Methods for treating obesity

ABSTRACT

The present invention relates to methods of treating overweight or obesity, reducing fat, sugar, and food intake, and reducing body weight or body weight gain in a subject using geranium oil or orlistat mouthwash, or a combination of both.

STATEMENT OF PRIORITY

This application claims the benefit of U.S. Provisional Application Ser.No. 62/203,119, filed Aug. 10, 2015, the entire contents of which areincorporated by reference herein.

FIELD OF THE INVENTION

The present invention relates to methods of treating overweight orobesity and reducing weight gain and food intake in a subject usingorlistat mouthwash and/or geranium oil.

BACKGROUND OF THE INVENTION

Obesity is worldwide health problem that is reaching epidemicproportions. Since 1980 the worldwide prevalence of obesity has morethan doubled. As of 2014 the World Health Organization estimates thatover 600 million adults are obese, comprising about 13% of the world'sadult population. Overweight and obesity are the fifth leading risk forglobal deaths.

Obesity is a complex disease influenced by genetics, diet, exercise, anda complex biology. Typical treatments are diet and exercise, howeversuch behavior modification is not efficacious in the long run for asignificant portion of patients. While bariatric surgery to reduce thesize of the stomach (gastric bypass surgery) is an effective treatmentfor causing weight loss in morbidly obese people, it is invasive,expensive and can have significant side effects. Current therapeuticsleave much to be desired. Orlistat, which blocks fat absorption in thegut, is one drug approved by the FDA for the long-term treatment ofobesity. However, side effects associated with orlistat administration,including oily spotting, oily fecal discharge, fecal urgency, and fecalincontinence, limit its appeal. Thus, development of improved obesitytreatments are urgently needed.

SUMMARY OF THE INVENTION

The present invention provides effective and convenient methods fortreatment or prevention of overweight or obesity and to help peoplereduce body weight and/or food intake. Methods utilizing both geraniumoil and orlistat mouthwash have been demonstrated to be beneficial.

Thus, one aspect of the present invention is directed to a method forreducing dietary fat intake in a subject in need thereof, comprisingadministering to the subject a mouthwash composition comprising atherapeutically effective amount of orlistat; thereby reducing dietaryfat intake.

In another aspect the present invention is directed to a method forreducing dietary sugar intake in a subject in need thereof, comprisingadministering to the subject a composition for oral administrationcomprising a therapeutically effective amount of geranium oil, therebyreducing dietary sugar intake.

In a further aspect the present invention is directed to a method fortreating overweight or obesity in a subject in need thereof, comprisingadministering to the subject a mouthwash composition comprising atherapeutically effective amount of orlistat, thereby treatingoverweight or obesity.

In an additional aspect the present invention is directed to a methodfor reducing body weight or body weight gain in a subject in needthereof, comprising administering to the subject a mouthwash compositioncomprising a therapeutically effective amount of orlistat, therebyreducing body weight.

In another aspect the present invention is directed to a method forreducing food intake in a subject in need thereof, comprisingadministering to the subject a mouthwash composition comprising atherapeutically effective amount of orlistat, thereby reducing foodintake.

In a further aspect the present invention is directed to a method fortreating overweight or obesity in a subject in need thereof, comprisingadministering to the subject a composition for oral administrationcomprising a therapeutically effective amount of geranium oil, therebytreating overweight or obesity.

In an additional aspect the present invention is directed to a methodfor reducing body weight or body weight gain in a subject in needthereof, comprising administering to the subject a composition for oraladministration comprising a therapeutically effective amount of geraniumoil, thereby reducing body weight.

In another aspect the present invention is directed to a method forreducing food intake in a subject in need thereof, comprisingadministering to the subject a composition for oral administrationcomprising a therapeutically effect amount of geranium oil, therebyreducing food intake.

In a further aspect the present invention is directed to a method forreducing dietary fat intake and/or dietary sugar intake in a subject inneed thereof, comprising administering to the subject: a) a compositioncomprising a therapeutically effective amount of geranium oil; and b) acomposition comprising a therapeutically effective amount of orlistat,thereby reducing dietary fat intake and/or dietary sugar intake.

In an additional aspect the present invention is directed to a methodfor reducing food intake in a subject in need thereof, comprisingadministering to the subject: a) a composition for oral administrationcomprising a therapeutically effective amount of geranium oil; and b) amouthwash composition comprising a therapeutically effective amount oforlistat, thereby reducing food intake.

In another aspect the present invention is directed to a method forreducing body weight or body weight gain in a subject in need thereof,comprising administering to the subject: a) a composition for oraladministration comprising a therapeutically effective amount of geraniumoil; and b) a mouthwash composition comprising a therapeuticallyeffective amount of orlistat, thereby reducing body weight.

In an a further aspect the present invention is directed to a method fortreating overweight or obesity in a subject in need thereof, comprisingadministering to the subject: a) a composition for oral administrationcomprising a therapeutically effective amount of geranium oil; and b) amouthwash composition comprising a therapeutically effective amount oforlistat, thereby treating overweight or obesity.

In an additional aspect the present invention is directed to a mouthwashcomposition comprising orlistat in an amount effective to treatoverweight or obesity in a subject.

In another aspect the present invention is directed to a composition fororal administration comprising geranium oil in an amount effective totreat overweight or obesity in a subject.

These and other aspects of the invention are set forth in more detail inthe description of the invention below.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows the results for a patch clamp assay on rodent taste budcells determining inhibition of taste receptors on the tongue bygeranium oil.

FIGS. 2A and 2B show the suppressing effect that activation ofintestinal taste receptors has on appetite and food intake in shamfeeding rats.

FIG. 3A shows the effects on total fat intake in 10 individuals who wereadministered orlistat mouthwash prior to a fatty meal.

FIG. 3B shows the effects on total caloric intake in 10 individuals whowere administered orlistat mouthwash prior to a fatty meal.

FIGS. 3C and 3D show the effects of orlistat mouthwash administeredprior to a fatty meal on total fat intake in individuals who ate largerand smaller portions.

DETAILED DESCRIPTION OF THE INVENTION

The present invention now will be described hereinafter with referenceto the accompanying examples, in which embodiments of the invention areshown. This invention may, however, be embodied in many different formsand should not be construed as limited to the embodiments set forthherein. Rather, these embodiments are provided so that this disclosurewill be thorough and complete, and will fully convey the scope of theinvention to those skilled in the art.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. The terminology used in thedescription of the invention herein is for the purpose of describingparticular embodiments only and is not intended to be limiting of theinvention.

All publications, patent applications, patents, patent publications andother references cited herein are incorporated by reference in theirentireties for the teachings relevant to the sentence and/or paragraphin which the reference is presented.

As used in the description of the invention and the appended claims, thesingular forms “a,” “an,” and “the” are intended to include the pluralforms as well, unless the context clearly indicates otherwise.

Also as used herein, “and/or” refers to and encompasses any and allpossible combinations of one or more of the associated listed items, aswell as the lack of combinations when interpreted in the alternative(“or”).

The term “about,” as used herein when referring to a measurable valuesuch as an amount of polypeptide, dose, time, temperature, enzymaticactivity or other biological activity and the like, is meant toencompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% ofthe specified amount.

As used herein, the transitional phrase “consisting essentially of”means that the scope of a claim is to be interpreted to encompass thespecified materials or steps recited in the claim and those that do notmaterially affect the basic and novel characteristic(s) of the claimedinvention. Thus, the term “consisting essentially of” when used in aclaim or the description of this invention is not intended to beinterpreted to be equivalent to “comprising.”

The term “inhibit” or “reduce” or grammatical variations thereof as usedherein refers to a decrease or diminishment in the specified level oractivity of at least about 15%, 25%, 35%, 40%, 50%, 60%, 75%, 80%, 90%,95% or more.

An “effective” amount as used herein is an amount that provides adesired effect.

A “therapeutically effective” amount as used herein is an amount thatprovides some improvement or benefit to the subject. Alternativelystated, a “therapeutically effective” amount is an amount that willprovide some alleviation, mitigation, or decrease in at least oneclinical symptom in the subject. Those skilled in the art willappreciate that the therapeutic effects need not be complete orcurative, as long as some benefit is provided to the subject.

By the terms “treat,” “treating,” or “treatment,” it is intended thatthe severity of the subject's condition is reduced or at least partiallyimproved or modified and that some alleviation, mitigation or decreasein at least one clinical symptom is achieved.

As used herein the term “body weight gain” refers to the increase inweight of a subject's body over time.

As used herein the term “food intake” refers to the intake of caloriesin any form, including without limitation, food and drink deliveredorally or enterally.

The phrase “treating overweight or obesity,” as used herein encompassesalleviating, mitigating, or decreasing at least one clinical symptom ofoverweight or obesity or slowing of progression of the clinicalsymptoms.

The term “mouthwash” as used herein refers to a liquid solution that isused by a subject to rinse the mouth then is spit out withoutsignificant amounts of the mouthwash being swallowed (e.g., less thanabout 10%, 5%, or 1%).

As used herein the term “obesity” refers to a body mass index (BMI)between 30 and 40 in adult humans.

For people under 20 “obesity” is defined as a BMI above the 95thpercentile compared to people of the same age in the US who participatedin the national surveys that were conducted from 1963-65 to 1988 to 94.As used herein, the term can include both obesity and morbid obesity.

As used herein the term “overweight” refers to a BMI between 25 and 30in adult humans.

The term “simultaneously” refers to actions occurring at the same timeor within about one minute of each other.

The term “sequentially” refers to actions in a sequence or a series ofevents. As used herein, the term refers to administration of one activeagent after another, e.g., within about 60 minutes of each other.

The present invention provides effective and convenient methods fortreatment or prevention of overweight or obesity and to help peoplereduce body weight and/or food intake. Both geranium oil and orlistatmouthwash have been demonstrated to be beneficial.

The present invention is based in part on the discovery that aneffective amount of geranium oil can suppress appetite and food intake.Without being limited by mechanism, it is thought that taste receptorson the tongue are inhibited and those in the mucosa of the smallintestine, including the duodenum, are activated by an effective amountof geranium oil, thereby suppressing appetite and food intake.

Geranium oil is an extract from Pelargonium graveolens, a species nativeto South Africa, Zimbabwe and Mozambique. Common names include “rosegeranium” and “old fashioned rose geranium.” Geranium oil is ahydrophobic liquid containing multiple species of organic compounds. Itis an “essential oil,” meaning that the extract has captured the“essence” of the plant. Essential oils are often extracted bydistillation, using steam. Other methods include solvent extraction.Geranium oil is commercially available.

A therapeutically effective amount of geranium oil can be delivered viaany suitable method known in the art. In one embodiment, the geraniumoil is delivered orally, e.g., in a capsule. Suitable delivery vehiclesinclude, without limitation, geranium oil in an acid resistant capsule,a water soluble dry form of geranium oil, and a water soluble dry formcontained in an acid resistant capsule. In any delivery vehicle thegeranium oil can be diluted about 1:100 to about 1:10,000, e.g., about1:100, 1:250, 1:500, 1:1000, 1:2000, 1:3000, 1:4000, 1:5000, or anyrange therein. Suitable diluents include, without limitation, water,physiologic saline, oils, other essential oils, creams, and otherliquids and semi-solids.

In some embodiments, a therapeutically effective amount of geranium oilmay be delivered prior to a meal. Prior to a meal means immediatelybefore eating, e.g., within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30,45, 60, 75, 90, 105, 120, 135, 150, 165, or 180 minutes prior to eating.In other embodiments, geranium oil may be taken before, during and/orafter a meal. In other embodiments, a therapeutically effective amountof geranium oil is delivered on a regular schedule, e.g., 1, 2, 3, 4, or5 times a day.

Another aspect of the present invention is based in part on thediscovery that an effective amount of orlistat mouthwash prior toconsumption of a fatty meal decreases food and fat calorie intake in fatpreferring people by approximately 20%. Without being limited bymechanism, it is thought that orlistat mouthwash inhibits lingual lipasethereby blocking the generation of free fatty acids from triglyceridehydrolysis. Fatty acids in the mouth are thought to signal the taste forfat through taste receptors to the brain. Abrogating this signal has asatiating effect thereby reducing fat intake. Administering orlistat asmouthwash provides beneficial effects without known side effectsassociated with capsules, including oily spotting, oily fecal discharge,fecal urgency, and fecal incontinence.

A therapeutically effective amount of orlistat can be delivered via anysuitable mouthwash composition known in the art. In one embodiment, theorlistat is delivered in an aqueous mouthwash comprising water andoptionally additional components such as salts, buffers, viscositymodifiers, flavorants, colorants, etc.

A therapeutically effective amount of orlistat mouthwash contains about1 mg to about 200 mg of orlistat per dose, e.g., about 1, 5, 10, 20, 30,40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180,190, or 200 mg or any range therein. In some embodiments, the dose maybe even higher, e.g., about 500 or 1000 mg or more as the majority ofthe dose may not be absorbed during the time the mouthwash is in contactwith the oral mucosa.

A therapeutically effective amount of orlistat mouthwash may beadministered prior to a meal. Prior to a meal means immediately beforeeating, e.g., within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 45,60, 75, 90, 105, 120, 135, 150, 165, and 180 minutes prior to eating. Inother embodiments, a therapeutically effective amount of orlistatmouthwash may be taken before, during, and/or after a meal. In otherembodiments, a therapeutically effective amount of geranium oil isdelivered on a regular schedule, e.g., 1, 2, 3, 4, or 5 times a day.

As used herein, the term “subject” refers to humans and other animals.Suitable subjects include mammals such as humans, as well as thosemammals of importance due to being endangered, such as Siberian tigers;of economic importance, such as animals raised on farms; animals ofsocial importance to humans, such as animals kept as pets or in zoos;and research animals, such as mice, rabbits, guinea pigs, ferrets, dogs,cats, monkeys, and apes. Examples of such animals include but are notlimited to: carnivores such as cats and dogs; swine, including pigs,hogs, and wild boars; ruminants and/or ungulates such as cattle, oxen,sheep, giraffes, deer, goats, bison, and camels; horses; and poultry.Human subjects include neonates, infants, juveniles, and adults. In someembodiments, the subject is an animal model of overweight or obesity. Insome embodiments, the subject is a fat-preferring subject.

As used herein, the term “fat-preferring subject” refers to subjectsthat crave fat-sweet and/or fat-protein foods or subjects that preferdiets composed of fat levels above the percent fat typically found inthe American diet (e.g., above about 35%).

In another aspect the present invention is directed to a method fortreating overweight or obesity, a method for reducing body weight orbody weight gain, a method for reducing food intake, and a method forreducing dietary fat intake and/or dietary sugar intake in a subject inneed thereof, comprising administering to the subject: a) a compositionfor oral administration comprising a therapeutically effective amount ofgeranium oil, and b) a mouthwash composition comprising atherapeutically effective amount of orlistat.

The combination of orally administered geranium oil and an orlistatmouthwash has two advantages over using either separately. First, thecombination may address both problems that lead to overweight orobesity, sweet or sugary foods and foods high in fat. By acting on bothtypes of food, the combined impact of geranium oil and orlistat mayreduce food intake to a greater degree, and be more effective in thetreatment of overweight or obesity. Secondly, by using geranium oil andorlistat together, the combination that will be effective for subjectswith either fat-sweet or fat-protein preferences. In certainembodiments, the combination of geranium oil and orlistat may haveadditive or synergistic effects on overweight or obesity, food intake,and/or weight loss.

A therapeutically effective amount of orlistat mouthwash and geraniumoil can be administered simultaneously or sequentially prior toconsumption of a meal. In other embodiments, the combination may betaken before, during, and/or after a meal. In other embodiments, thecombination may be delivered on a regular schedule, e.g., 1, 2, 3, 4, or5 times a day.

In another aspect the present invention is directed to any of the abovedisclosed combinations of orlistat and geranium oil. In one aspect, theinvention is directed to a composition for oral administrationcomprising geranium oil in an amount effective to treat overweight orobesity in a subject. In one embodiment, said geranium oil is containedin an acid resistant capsule. In one embodiment, the geranium oil is ina water soluble dry form, e.g., in an acid resistant capsule. Thegeranium oil may be diluted about 1:100 to about 1:1000.

Another aspect the present invention is directed to a mouthwashcomposition comprising orlistat in an amount effective to treatoverweight or obesity in a subject. In one embodiment, the orlistatmouthwash contains about 1 mg to about 120 mg orlistat per dose.

A further aspect the present invention is directed to a combinationcomprising the geranium oil composition of the invention and an orlistatmouthwash composition of the invention. The combination may be in theform of a kit. The geranium oil composition and orlistat mouthwashcomposition may be in separate containers. The combination or kit mayfurther comprise other components, such as delivery devices, dosagemeasuring cups, etc.

The present invention is more particularly described in the followingexamples that are intended as illustrative only since numerousmodifications and variations therein will be apparent to those skilledin the art.

Example 1 Activation of Duodenal Fatty Acid-Sensitive Taste Receptors byGeranium Oil

It was previously demonstrated that 10 ppm geranium oil inhibits thetaste receptor on the tongue by 60.5% (FIG. 1). Importantly, it has beenshown that similar fatty acid-sensitive taste receptors are present inthe mucosa of the small intestine, including the duodenum. Todemonstrate that activation of these intestinal taste receptor cells cansuppress appetite and food intake, geranium oil or saline were infuseddirectly into the duodenum of sham-feeding rats. A fistula was made fromthe stomach to the abdominal wall in a rat, so that the rat willcontinually drink a 15% sucrose solution that is collected through atube. Geranium oil diluted 1:1000 in water was tested in 3 sham-fed rats(FIGS. 2A and 2B). The results showed that duodenal infusion at 0.2mL/min of a geranium oil solution for 15 minutes significantlyattenuated consumption of the 15% sucrose solution. These resultsdemonstrate that geranium oil could reduce caloric intake and causeweight loss, if delivered to the duodenum in the correct concentration.

Example 2 Orlistat Mouthwash Decreases Food and Energy Intake

The effect of orlistat mouthwash (OM) on fat intake was determined by adouble-blind, placebo controlled, randomized and balanced crossoverstudy performed on 10 healthy individuals between 18 and 70 years of ageand a body mass index (BMI) between 25 and 35 kg/m².

Prospective subjects were recruited during a screening visit in whichthey completed a medical questionnaire, a menstrual questionnaire todetermine the ideal study period in females (luteal phase) and a3-factor eating questionnaire (measuring dietary restraint, inhibitionand hunger). Inclusion criteria included healthy male and femalesbetween 18-70 years of age with a BMI between 25-35 kg/m². Exclusionsincluded pregnancy, a restraint score of greater than 13 or asignificant aversion to the test food (as determined by a sampletasting). Also excluded were any subjects taking diabetic medications,systemic glucocorticoids or any agent that was known to cause weight orappetite changes. Approximately 1-2 minutes before eating, subjectsswished approximately 2 teaspoons of OM (240 mg/10 mL) or a placebosolution in their mouth for 30 seconds before spitting out the solution.Subjects were then given the high-fat test meal (multiple servings ofJohnsonville® Bratwurst: (21 grams of fat per serving)). Subjects wereallowed to eat ad libitum for 20 minutes. Test meal contents wereweighed before and after testing and determinations were made tocalculate total caloric (energy) and total fat intake during the meal.(FIGS. 3A and 3B) Patients were their own controls. Fat intake andappetite ratings were compared using paired t-tests. Non-parametric datalike adverse events were analyzed using the chi-squared test.Statistical significance was set at an alpha of 0.05. Subjects consumed15.51±219.38 kcal less fat (FIG. 3A) and 20.14±279.81 kcal less totalenergy (FIG. 3B) following the OM compared to the placebo mouthwash.

While treatment with OM did not significantly reduce food intakeoverall, among the high food intake (fat-preferring, i.e., those thatate an amount of sausage above the mean) individuals a statisticallysignificant decrease was observed, both when measured as fold change infat intake (FIG. 3C) and total intake (FIG. 3D). This suggests that OMmay be especially effective in fat-preferring subjects.

The foregoing is illustrative of the present invention, and is not to beconstrued as limiting thereof. The invention is defined by the followingclaims, with equivalents of the claims to be included therein.

1. A method for treating overweight or obesity in a subject in needthereof, comprising administering to the subject: a) a composition fororal administration comprising a therapeutically effective amount ofgeranium oil; and b) a mouthwash composition comprising atherapeutically effective amount of orlistat; thereby treatingoverweight or obesity.
 2. A method for reducing body weight or bodyweight gain in a subject in need thereof, comprising administering tothe subject: a) a composition for oral administration comprising atherapeutically effective amount of geranium oil; and b) a mouthwashcomposition comprising a therapeutically effective amount of orlistat;thereby reducing body weight or body weight gain.
 3. A method forreducing food intake in a subject in need thereof, comprisingadministering to the subject: a) a composition for oral administrationcomprising a therapeutically effective amount of geranium oil; and b) amouthwash composition comprising a therapeutically effective amount oforlistat; thereby reducing food intake.
 4. A method for reducing dietaryfat intake and/or dietary sugar intake in a subject in need thereof,comprising administering to the subject: a) a composition comprising atherapeutically effective amount of geranium oil; and b) a compositioncomprising a therapeutically effective amount of orlistat; therebyreducing dietary fat intake and/or dietary sugar intake.
 5. The methodof any one of claims 1-4, wherein the geranium oil and orlistat areadministered simultaneously or sequentially prior to consumption of ameal.
 6. The method of any one of claims 1-5, wherein the geranium oilis administered in water soluble dry form.
 7. The method of any one ofclaims 1-6, wherein the geranium oil is administered at a dilution ofabout 1:100 to about 1:10,000.
 8. The method of any one of claims 1-7,wherein the geranium oil is administered in an acid resistant capsule.9. The method of any one of claims 1-8, wherein the orlistat mouthwashcontains about 1 mg to about 200 mg orlistat.
 10. A method for treatingoverweight or obesity in a subject in need thereof, comprisingadministering to the subject a composition for oral administrationcomprising a therapeutically effective amount of geranium oil, therebytreating overweight or obesity.
 11. A method for reducing body weight orbody weight gain in a subject in need thereof, comprising administeringto the subject a composition for oral administration comprising atherapeutically effective amount of geranium oil, thereby reducing bodyweight.
 12. A method for reducing food intake in a subject in needthereof, comprising administering to the subject a composition for oraladministration comprising a therapeutically effective amount of geraniumoil, thereby reducing food intake.
 13. A method for reducing dietarysugar intake in a subject in need thereof, comprising administering tothe subject a composition for oral administration comprising atherapeutically effective amount of geranium oil, thereby reducingdietary sugar intake.
 14. The method of any one of claims 10-13, whereinthe geranium oil is administered prior to a meal.
 15. The method of anyone of claims 10-14, wherein the geranium oil is administered in a watersoluble dry form.
 16. The method of any one of claims 10-15, wherein thegeranium oil is administered at a dilution of about 1:100 to about1:10,000.
 17. The method of any one of claims 10-16, wherein thegeranium oil is administered in an acid resistant capsule.
 18. A methodfor treating overweight or obesity in a subject in need thereof,comprising administering to the subject a mouthwash compositioncomprising a therapeutically effective amount of orlistat; therebytreating overweight or obesity.
 19. A method for reducing body weight orbody weight gain in a subject in need thereof, comprising administeringto the subject a mouthwash composition comprising a therapeuticallyeffective amount of orlistat; thereby reducing body weight.
 20. A methodfor reducing food intake in a subject in need thereof, comprisingadministering to the subject a mouthwash composition comprising atherapeutically effective amount of orlistat; thereby reducing foodintake.
 21. A method for reducing dietary fat intake in a subject inneed thereof, comprising administering to the subject a mouthwashcomposition comprising a therapeutically effective amount of orlistat;thereby reducing dietary fat intake.
 22. The method of any one of claims18-21, wherein the orlistat mouthwash is administered prior to a meal.23. The method of any one of claims 18-22, wherein said orlistatmouthwash contains about 1 mg to about 200 mg orlistat.
 24. Acomposition for oral administration comprising geranium oil in an amounteffective to treat overweight or obesity in a subject.
 25. Thecomposition of claim 24, wherein the geranium oil is in a water solubledry form.
 26. The composition of claim 25, wherein the water soluble drygeranium oil is contained in an acid resistant capsule.
 27. Thecomposition of claim 24, wherein the geranium oil is diluted about 1:100to about 1:10,000.
 28. The composition of claim 24, wherein saidgeranium oil is contained in an acid resistant capsule.
 29. (canceled)30. (canceled)
 31. (canceled)
 32. (canceled)
 33. A combinationcomprising: a) a composition for oral administration comprising geraniumoil in an amount effective to treat overweight or obesity in a subject;and b) a mouthwash composition comprising orlistat in an amounteffective to treat overweight or obesity in a subject.
 34. A kitcomprising a) a composition for oral administration comprising geraniumoil in an amount effective to treat overweight or obesity in a subject;and b) a mouthwash composition comprising orlistat in an amounteffective to treat overweight or obesity in a subject